Boehringer backs $33M can­cer vac­cine play at Switzer­land's AMAL Ther­a­peu­tics

A can­cer vac­cine de­vel­op­er spun out of the Uni­ver­si­ty of Gene­va has gar­nered €29 mil­lion ($32.7 mil­lion) to fu­el its dri­ve in­to the clin­ic.

AMAL Ther­a­peu­tics man­aged to con­vince all the in­vestors who col­lec­tive­ly gave €8 mil­lion last Sep­tem­ber to step up their com­mit­ment in this sec­ond clos­ing of the Se­ries B, fea­tur­ing co-lead­ers Boehringer In­gel­heim Ven­ture Fund, Bio­Med Part­ners and Helsinn In­vest­ment Fund in ad­di­tion to VI Part­ners, Schroder Ad­veq and High-Tech Grün­der­fonds.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER